Jefferies raises Scholar Rock stock price target on BLA resubmission By Investing.com

Scholar Rock resubmitted its BLA for apitegromab and Jefferies raised its price target to $57 (from $54); shares trade at $49.10, up 64% over the past year and near a 52‑week high of $50.50. Jefferies expects FDA approval in 2026 with a PDUFA in late Sept 2026 and a conservative launch in Q4 2026; other firms raised or reiterated targets (BofA $58, Truist $55, BMO $70). Roche’s discontinuation of rival emugrobart reduces near‑term competitive risk, while the BLA resubmission includes an additional U.S. fill/finish site to derisk timing despite a prior Complete Response Letter tied to Catalent inspection observations.

Analysis

The regulatory path here creates concentrated optionality: a successful approval would convert a single clinical/regulatory binary into multi-year commercial optionality in a narrow therapeutic class, giving the incumbent disproportionate pricing power but also exposing them to payer-driven volume caps or outcomes contracts that can shave realized revenue by a material percentage versus list price. Manufacturing redundancy (adding a second fill/finish source) materially reduces single-point-of-failure risk, but it also introduces coordination friction—inventory phasing, lot-release harmonization, and parallel validation can delay first commercial shipments by 3–9 months even after approval, which is an underappreciated timing risk to revenue recognition.

Second-order competitive effects favor firms that control downstream manufacturing or distribution: a strategic buyer with CDMO/logistics assets could rapidly convert approval into scale and limit third-party negotiation leverage—this creates a latent M&A premium that the market can reprice quickly if manufacturing blips persist. Conversely, payers and PBMs hold strong bargaining leverage in pediatric/adolescent indications; commercial uptake and realized pricing are therefore as dependent on contracting milestones (rebates, performance guarantees) in the first 12–24 months as they are on label breadth.

The consensus appears to be pricing substantial approval probability today; that makes implied volatility asymmetric — upside is capped by competition/payer erosion while downside is binary (manufacturing/regulatory delay). For our portfolio the highest-expected-value structures are those that: (1) buy upside with defined downside (financed call spreads), (2) protect exposure with cheap put spreads around inspection or advisory milestones, and (3) collect premium on short-dated optimism runs to finance longer-dated optionality.

Key Decisions for Investors

• Directional (defined-risk beta): SRRK — Buy a 12–18 month call spread (e.g., buy Jan-2028 calls / sell higher-strike Jan-2028 calls to finance) sized to 2–4% of biotech book. R/R: limited downside = premium paid; upside capped but >2x if approval + clean manufacturing timeline; objective is to capture approval re-rate while avoiding large capital at risk on a single binary.
• Tail protection: SRRK — Buy a 6–9 month put spread (30–40% OTM) to hedge existing equity exposure across the inspection/labeling review window. R/R: modest premium (~<5% equity notional) buys protection against a regulatory/manufacturing-driven and rapid >30% downside.
• Vol套利 (sell momentum): SRRK — Sell 2–3 month call spreads 5–10% OTM into analyst-driven spikes to harvest IV; roll loser positions past major milestones. R/R: collect premium to finance longer-dated calls; risk of assignment on big positive surprise but manageable via hedges.
• Event / corporate strategy play: Accumulate SRRK on 10–20% pullbacks into a staggered buy program (scale in at two tranches) with an explicit 12–18 month view for either M&A or commercialization optionality. R/R: asymmetric payoff if market re-rates for takeover or clean approval; downside limited by staged sizing and put protection.